BHRT vs HRT: What the Difference Actually Is, and What the Evidence Shows

"BHRT" and "HRT" are not rival treatments — BHRT describes hormone molecules chemically identical to the ones your ovaries produced, and HRT is the umbrella term covering those alongside others whose structure has been deliberately modified. What changes your outcome is which molecule, by which route, and how close to your final period you begin.

The short version. Estradiol and progesterone prescribed for menopause are bioidentical, and many are FDA-approved products stocked at any pharmacy. "Bioidentical" describes molecular structure — not where a prescription was filled, and not a synonym for "compounded." Separate those ideas and the real questions appear: estradiol or a conjugated estrogen mixture, patch or pill, micronized progesterone or a synthetic progestin, and when you start.

Why "BHRT vs HRT" Is the Wrong Comparison

HRT — or, as clinicians now say, menopausal hormone therapy — is defined by what a treatment does. BHRT is defined by what the molecule looks like. Those are different kinds of statement, so one cannot be the alternative to the other. A 17-beta-estradiol patch is simultaneously HRT and bioidentical.

The confusion is not accidental. An ACOG Clinical Consensus document is direct about its origin: many compounding pharmacies use "bioidentical hormone" as a marketing term to imply these preparations are safer than FDA-approved menopausal medications — which themselves may use bioidentical hormones, synthetic hormones, or both (ACOG Clinical Consensus No. 6, Obstet Gynecol, 2023, DOI).

The molecular comparison, and everything that follows from it, is on this page. If your next question is which labs get drawn before and during treatment, what each marker means and how often it is repeated, that is covered separately in our guide to hormone testing and monitoring for bioidentical hormone therapy.

What "Bioidentical" Means at the Molecular Level

A bioidentical hormone has a molecular structure identical to the hormone your body produced endogenously (Borda et al., Dermatol Online J, 2019, PubMed) — here, 17-beta-estradiol, progesterone and testosterone. The non-identical alternatives are conjugated equine estrogens, sourced from pregnant mare urine, and synthetic progestins such as medroxyprogesterone acetate: progesterone-like molecules with atoms added, removed or rearranged.

Why should a few atoms matter? Because shape determines what a molecule binds and how long it lasts. Progesterone and the progestins are non-selective ligands for the progesterone receptor and also bind other steroid receptors, with agonist or antagonist effects depending on the molecule's structure; half-life and metabolism differ too (Gompel & Plu-Bureau, Climacteric, 2018, DOI). A synthetic progestin is a different key, and it opens some locks progesterone does not.

That is the legitimate core of the bioidentical argument. What it does not license is the leap from "structurally identical" to "risk-free," or to "must be compounded."

Bioidentical Hormones You Can Get as FDA-Approved Products

This is the fact most often left out. A 2023 JAMA review states plainly that bioidentical estrogens approved by the FDA — chemically identical to naturally produced estrogens, often administered transdermally — are available to treat vasomotor symptoms (Crandall et al., JAMA, 2023, DOI). Estradiol patches, gels, sprays and vaginal preparations are bioidentical, as is oral micronized progesterone — each made to pharmaceutical standards with labeled dosing. You rarely have to choose between "bioidentical" and "well studied."

Compounded preparations are hormones mixed to order by a pharmacy, often in custom ratios, as creams, troches or pellets. Compounding has a real role — an allergy to an excipient in every commercial product, or a dose or delivery form that does not exist commercially (Pinkerton, Cancer J, 2022, DOI). Outside those situations ACOG recommends counseling patients that FDA-approved therapies are the recommended option, and notes that randomized trials comparing compounded with approved products would settle the question (ACOG, 2023, DOI); the FDA-commissioned National Academies investigation reached conclusions in harmony with global menopause societies (Stuenkel, Climacteric, 2021, DOI). If you are told bioidentical hormones come only from compounding, that is a claim about a business model, not pharmacology.

What the Women's Health Initiative Actually Found

The WHI estrogen-plus-progestin trial randomized 16,608 postmenopausal women aged 50 to 79 with an intact uterus to conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d or placebo, stopping at a mean 5.2 years. Hazard ratios were 1.29 for coronary heart disease, 1.26 for invasive breast cancer, 1.41 for stroke, 2.13 for pulmonary embolism, 0.63 for colorectal cancer and 0.66 for hip fracture. In absolute terms: 7 more coronary events, 8 more strokes, 8 more pulmonary emboli and 8 more invasive breast cancers per 10,000 women per year, and 6 fewer colorectal cancers and 5 fewer hip fractures (Rossouw et al., JAMA, 2002, DOI).

Eight additional breast cancers per 10,000 women per year is 0.08 percent per year. The headline was "26 percent increase." Both are correct and describe the same finding. That gap is the largest source of distorted risk perception in menopause care, which is why we quote absolute numbers.

Two more findings deserve airtime. Across both trials in 27,347 women followed 18 years, all-cause mortality was 27.1 percent with hormone therapy versus 27.6 percent with placebo (HR 0.99, 95% CI 0.94-1.03), with no significant difference in cardiovascular or cancer mortality (Manson et al., JAMA, 2017, DOI).

And the estrogen-alone arm went the other way. After more than 20 years of median follow-up, women with a prior hysterectomy given conjugated equine estrogens alone had significantly lower breast cancer incidence than placebo (238 versus 296 cases; HR 0.78, 95% CI 0.65-0.93) and lower breast cancer mortality (HR 0.60, 95% CI 0.37-0.97), while estrogen plus medroxyprogesterone acetate showed higher incidence (HR 1.28, 95% CI 1.13-1.45) but no significant mortality difference (HR 1.35, 95% CI 0.94-1.95) (Chlebowski et al., JAMA, 2020, DOI). The signal tracked with the progestogen — a finding about formulation that bears directly on the BHRT question.

Three Things That Changed After 2002

Timing

Mean age at WHI randomization was 63.4 — more than a decade past average menopause. Analyzed by age group, the ratio of nominal hazard ratios for all-cause mortality comparing women aged 50 to 59 with those aged 70 to 79 was 0.61 (95% CI 0.43-0.87) during the intervention phase (Manson et al., 2017, DOI).

ELITE tested this directly, randomizing 643 healthy postmenopausal women — fewer than 6 years or 10 or more years past menopause — to oral 17-beta-estradiol or placebo. After a median 5 years the effect on carotid intima-media thickness differed significantly between strata (P = 0.007 for interaction): in the early group CIMT increased 0.0044 mm per year on estradiol versus 0.0078 on placebo (P = 0.008), while the late group showed no difference (Hodis et al., N Engl J Med, 2016, DOI). The authors' own limitation: CT measures of coronary calcium, stenosis and plaque did not differ in either stratum, and CIMT is a surrogate, not a count of heart attacks.

The 2022 North American Menopause Society position statement reflects this: for women under 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favorable for treating bothersome vasomotor symptoms and preventing bone loss; beyond that window it appears less favorable because of greater absolute risks (NAMS, Menopause, 2022, DOI).

Formulation

WHI tested oral conjugated equine estrogens with or without oral medroxyprogesterone acetate. It did not test transdermal estradiol or micronized progesterone. Extending its findings to every regimen ever prescribed is an inference it cannot support — which is equally why nobody should claim WHI proves estradiol and progesterone are safe. It did not test them.

Absolute versus relative risk

The 2023 JAMA review gives a figure worth memorizing: the increased risk of stroke and venous thromboembolism with conjugated equine estrogens, and of breast cancer with the combination, is approximately 1 excess event per 1,000 person-years — and systemic estrogen reduces vasomotor symptom frequency by roughly 75 percent, with oral and transdermal similarly effective (Crandall et al., 2023, DOI).

Route: Why Transdermal Estradiol Behaves Differently

A swallowed estrogen passes through the liver first, and that pass changes hepatic output of clotting factors, sex hormone-binding globulin and inflammatory proteins. A patch or gel largely bypasses it: transdermal estrogens have less effect on coagulation, inflammation and lipids than oral (Shufelt & Manson, J Clin Endocrinol Metab, 2021, DOI).

A meta-analysis found that among estrogen-only users, oral estrogen increased VTE risk (RR 1.48, 95% CI 1.39-1.58) while transdermal did not (RR 0.97, 95% CI 0.87-1.09) (Scarabin, Climacteric, 2018, DOI). For stroke, a nested case-control study of 15,710 cases and 59,958 controls found transdermal use carried an adjusted rate ratio of 0.95 (95% CI 0.75-1.20) versus no use, and low-dose patches 0.81 (0.62-1.05) — but high-dose patches 1.89 (1.15-3.11), and oral use 1.28 (1.15-1.42) (Renoux et al., BMJ, 2010, DOI). Route is not a free pass; dose counts.

Now the counterweight. A cohort of 51,571 women veterans found VTE risk similar among users of oral conjugated equine estrogens, oral estradiol and transdermal estradiol (transdermal versus CEE, HR 0.95, 95% CI 0.60-1.49); the authors wrote that their findings do not confirm the previously observed greater safety of transdermal estradiol over CEE (Blondon et al., Menopause, 2021, DOI). The transdermal advantage is coherent and widely supported, but unproven by randomized trial.

Micronized Progesterone Versus Synthetic Progestins

If you have a uterus and take systemic estrogen you need a progestogen, and bioidentical progesterone does that job. In the PEPI trial, 596 postmenopausal women were followed three years. Unopposed conjugated estrogen produced simple hyperplasia in 27.7 percent versus 0.8 percent on placebo, and atypical hyperplasia in 11.8 versus 0 percent. All three estrogen-plus-progestogen regimens — including 200 mg/d micronized progesterone for 12 days per cycle — had hyperplasia rates similar to placebo (P = 0.16) (PEPI Writing Group, JAMA, 1996, DOI). That protection is established by randomized trial, not inferred.

The breast signal is where progestogens separate. In the French E3N cohort, 80,377 postmenopausal women were followed a mean 8.1 postmenopausal years, during which 2,354 invasive breast cancers occurred. Relative to never-use, estrogen with progesterone carried an RR of 1.00 (95% CI 0.83-1.22), estrogen with dydrogesterone 1.16 (0.94-1.43), and estrogen with other progestagens 1.69 (1.50-1.91) (Fournier et al., Breast Cancer Res Treat, 2008, DOI). That study found no difference by route of estrogen administration for breast cancer risk — a result that cuts against part of the standard bioidentical pitch.

For clotting, progestogen choice mattered again. Among transdermal estrogen users, micronized progesterone showed no change in VTE risk (RR 0.93, 95% CI 0.65-1.33) while norpregnane derivatives carried RR 2.42 (1.84-3.18); with oral estrogen, medroxyprogesterone acetate carried RR 2.77 (2.33-3.30) (Scarabin, 2018, DOI). Progestogens also blunt estrogen's favorable lipid effects, with micronized progesterone producing the smallest attenuation (Shufelt & Manson, 2021, DOI).

The honest caveat: these are observational data. No large randomized trial has compared transdermal estradiol plus micronized progesterone against conjugated estrogen plus medroxyprogesterone acetate for clinical events. The pattern is consistent and mechanistically sensible — but it is not the grade of evidence WHI provides.

Who Each Approach Suits, and How We Monitor

This is decided in a room with your history in front of us, and nothing here is a recommendation for any individual. It turns on how far you are from your final period (NAMS, 2022, DOI); your clotting and vascular history, since prior VTE, thrombophilia, migraine with aura and blood pressure move the route decision; whether you still have a uterus; your breast history; and which symptoms are bothering you.

NAMS recommends treatment be individualized, with periodic reevaluation of whether to continue (NAMS, 2022, DOI). That means a real baseline — symptom inventory, blood pressure, personal and family history, current mammography, lipids, fasting glucose and A1c, thyroid and a metabolic panel — then structured follow-up rather than an annual refill. One point deserves plain speaking, because it is where marketing lives: systemic estrogen is titrated to your symptoms and tolerance, not to a number on a lab slip. Levels confirm absorption and check for unintentionally high exposure; they are not a scoreboard. Any unscheduled or postmenopausal bleeding is evaluated regardless of what labs show.

How the Decision Gets Made at Arbour Longevity

We start with a history and an examination, not a product, and we set the follow-up interval before you leave. Most women who ask us for BHRT want two things: hormones matching what their body used to make, and a clinician who will tell them the truth about risk in numbers they can hold. Neither requires picking a side in a marketing argument. Read more about our approach to hormone replacement therapy in Ann Arbor, our work as a menopause specialist in Ann Arbor, and longer-term hormone optimization.

Frequently Asked Questions

Is BHRT safer than HRT?

Not as asked, because BHRT is a subset of HRT, not an alternative to it. The answerable version is whether estradiol and micronized progesterone are safer than conjugated equine estrogens and medroxyprogesterone acetate. Observational evidence points that way on clotting and breast outcomes (Scarabin, 2018, DOI; Fournier et al., 2008, DOI), but no randomized trial has compared them head to head.

Do I have to use a compounding pharmacy to get bioidentical hormones?

No. FDA-approved bioidentical estrogens are available, frequently in transdermal form, and are recommended for vasomotor symptoms (Crandall et al., 2023, DOI); oral micronized progesterone is likewise approved. Compounding has a legitimate role when an approved product genuinely will not work for you (Pinkerton, 2022, DOI).

Does the WHI mean hormone therapy causes breast cancer?

It means one specific combination was associated with 8 additional invasive breast cancers per 10,000 women per year (Rossouw et al., 2002, DOI). In the same program, estrogen alone after hysterectomy was associated with significantly lower breast cancer incidence and mortality over 20-plus years (Chlebowski et al., 2020, DOI), and all-cause mortality at 18 years was not increased (Manson et al., 2017, DOI).

Why might a patch be preferred over a pill?

Because a swallowed estrogen passes through the liver first and shifts production of clotting proteins, while a transdermal one largely does not (Shufelt & Manson, 2021, DOI). In meta-analysis, oral estrogen-only therapy raised VTE risk (RR 1.48) while transdermal did not (RR 0.97) (Scarabin, 2018, DOI) — though one veterans cohort did not reproduce it (Blondon et al., 2021, DOI).

I am 58 and eight years past my last period. Is it too late?

Not automatically. NAMS describes a favorable benefit-risk ratio for women under 60 or within 10 years of menopause onset without contraindications (NAMS, 2022, DOI). You are inside it on both counts — the start of a conversation about your risk profile, not a decision.

Which labs will I need, and how often?

A baseline panel and a recheck at 4 to 6 weeks, then periodically. What goes on the panel and what each marker actually means is set out in our guide to hormone testing and monitoring.

Hormone Consultations in Ann Arbor

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner and founder of Arbour Longevity. We are at 2217 Packard St #15, in the Eastover Professional Center, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside — no meters, no structure. Suite 15 is down a flight of stairs; if stairs are difficult for you, please call (734) 436-3357 before your visit.

Call (734) 436-3357 or book your first visit. The first visit is $35, applied toward your treatment plan. Cash pay, HSA and FSA accepted. For more on the cost of bioidentical hormone therapy in Michigan, see our guide to BHRT cost in Michigan.

Clinical information here is drawn from articles retrieved from PubMed and provided for education. It is not medical advice, a diagnosis, or a promise of any result.